Essential Partners
ACRS icon

Essential Partners’s Aclaris Therapeutics ACRS Stock Holding History

Essential Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26 Hold
5
– – ﹤0.01% 2810
2026
Q2 		$26 Hold
5
– – ﹤0.01% 2820
2026
Q1 		$19 Hold
5
– – ﹤0.01% 2824
2025
Q4 		$15 Buy
+5
New +$13 ﹤0.01% 2732

Other funds holding ACRS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
CRA Financial Services
CRA Financial Services Northfield, New Jersey $904M AUM 20.1% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Essential Partners's ACRS Position: Q3 2026 in Review

Essential Partners held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 5 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #2810.

Essential Partners first reported a position in ACRS in Q4 2025 and has held it in 4 quarters since. 13 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Essential Partners held 5 shares of Aclaris Therapeutics worth $26 as of Q3 2026.
  • Essential Partners left its Aclaris Therapeutics share count unchanged in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2810 holding.
  • Essential Partners first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 13 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.